Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: A retrospective study of 300 patients

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 112-120

  Nagy Mignotte, Hélène ^a,b   Guillem, Pascale ^a,b   Vignoud, Lucile ^b   Coudurier, Marie ^a   Vesin, Aurélien ^b   Bonneterre, Vincent ^a   Toffart, Anne Claire ^a,b   Sakhri, Linda ^a   Brambilla, Christian ^a,b   Brambilla, Elisabeth ^a,b   Timsit, Jean François ^a,b   Moro Sibilot, Denis ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT ALBERT BONNIOT   (France)

Author keywords

Chemotherapy lines; Prognosis; Recurrence; Sensitivity to treatment; Small cell lung cancer; Survival

Indexed keywords

CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PARANEOPLASTIC SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84866151603     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.06.006     Document Type: Article

References (40)

1. Tiseo M., Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2007, 2:764-772.
2. Lee P. Lung cancer: recent advances. Ann Acad Med Singapore 2010, 39(11):819-821.
3. Lally B.E., Geiger A.M., Urbanic J.J., Butler J.M., Wentworth S., Perry M.C., et al. Trends in the outcomes for patients with limited stage small cell lung cancer: an analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer 2009, 64(2):226-231.
4. El Maalouf G., Rodier J.M., Faivre S., Raymond E. Could we expect to improve survival in small cell lung cancer?. Lung Cancer 2007, 57(Suppl. 2):S30-S34.
5. Stupp R., Monnerat C., Turrisi A.T., Perry M.C., Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004, 45(1):105-117.
6. Riemsma R., Simons J.P., Bashir Z., Gooch C.L., Kleijnen J. Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010, 10:436.
7. Pirker R., Berzinec P., Brincat S., Kasan P., Ostoros G., Pesek M., et al. Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer 2010, 70:7-13.
8. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24(28):4539-4544.
9. Fried L., Bernardini J., Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001, 37(2):337-342.
10. French national insurance system for salaried workers (CNAM-TS), European Occupational Diseases Statistics Classification of the causal agents of the occupational diseases (EODS causal agent codes) http://circa.europa.eu/Public/irc/dsis/hasaw/library%3Fl=/occupational_statistics/working_paper_18/_EN_1.0_.
11. Duffaud F., Therasse P. Nouvelles recommandations pour l'évaluation de la réponse tumorale dans les tumeurs solides. Bull du cancer 2000, 87(12):881-886.
12. Garassino M.C., Torri V., Michetti G., Lo Dico M., La Verde N., Aglione S., et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer 2011, 72(3):378-383.
13. Nagy-Mignotte H., Guillem P., Vesin A., Toffart A.C., Colonna M., Bonneterre V., et al. Primary lung adenocarcinoma: characteristics by gender and smoking habit. Eur Respir J 2011, 38:1412-1419.
14. Quoix E., Mennecier B. Cancer du poumon et pollution. Rev Pneumol Clin 2003, 59:187-195.
15. Quoix E. Particularités du cancer bronchique chez la femme. Revue de pneumologie clinique: le poumon et le cœur 2004; 60 N°5 cahier 3:27-30.
16. Levin J.L., O'Sullivan M.F., Corn C.J., Williams M.G., Dodson R.F. Asbestosis and small cell lung cancer in a clutch refabricator. Occup Environ Med 1999, 56(9):602-605.
17. Littman A.J., Thornquist M.D., White E., Jackson L.A., Goodman G.E., Vaughan T.L. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004, 15(8):819-827.
18. Mollo F., Bellis D., Andreozzi A., Burlo P., Bo P., Cravello M. Lung cancers attributable to asbestos on a pathological basis. G Ital Med Lav Ergon 1997, 19(1):36-38.
19. Paris C. Facteurs de risques professionnels et extraprofessionnels des cancers bronchiques. Oncologie thoracique: synthèse des connaissances et perspectives 2002, 35-43. Editions Margaux Orange, Paris. L. Thiberville (Ed.).
20. Kayser K., Becker C., Seeberg N., Gabius H.J. Quantitation of asbestos and asbestos-like fibers in human lung tissue by hot and wet ashing, and the significance of their presence for survival of lung carcinoma and mesothelioma patients. Lung Cancer 1999, 24(2):89-98.
21. MacArthur A.C., Le N.D., Fang R., Band P.R. Identification of occupational cancer risk in British Columbia: a population-based case-control study of 2,998 lung cancers by histopathological subtype. Am J Ind Med 2009, 52(3):221-232.
22. National Toxicology Program Final report on carcinogens background document for formaldehyde. Rep Carcinog Backgr Doc 2010, (10-5981):i-512.
23. Massarelli E., Andre F., Liu D.D., Lee J.J., Wolf M., Fandi A., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003, 39(1):55-61.
24. Oze I., Hotta K., Kiura K., Ochi N., Takigawa N., Fujiwara Y., et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009, 4(11):e7835.
25. Isobe K., Kobayashi K., Kosaihira S., Kurimoto F., Sakai H., Uchida Y., et al. Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer. Lung Cancer 2009, 66(December (3)):350-354.
26. Park S., Ahn M.J., Ahn J.S., Lee J., Hong Y.S., Park B.B., et al. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. Lung Cancer 2007, 58(October (1)):116-122.
27. O'Brien M.E., Ciuleanu T.E., Tsekov H., Shparyk Y., Cuceviá B., Juhasz G., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24(34):5441-5447.
28. Mennecier B., Moreau L., Goichot B., Pauli G., Quoix E. Paraneoplastic Cushing's syndrome and small cell bronchial carcinoma. Rev Pneumol Clin 1999, 55(2):77-80.
29. Ilias I., Torpy D.J., Pacak K., Mullen N., Wesley R.A., Nieman L.K. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005, 90(8):4955-4962.
30. Temel J.S., Greer J.A., Muzikansky A., Gallagher E.R., Admane S., Jackson V.A., et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010, 363(8):733-742.
31. El-Jawahri A., Greer J.A., Temel J.S. Does palliative care improve outcomes for patients with incurable illness? A review of the evidence. J Support Oncol 2011, 9(3):87-94.
32. Lebeau B. Traitement des formes localisées des cancers à petites cellules. Oncologie thoracique: synthèse des connaissances et perspectives 2002, 355-360. Editions Margaux Orange, Paris. L. Thiberville (Ed.).
33. Arriagada R., Pignon J.P., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L., et al. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Res 1994, 14(1B):333-335.
34. Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992, 327(23):1618-1624.
35. Brambilla E., Negoescu A., Gazzeri S., Lantuejoul S., Moro D., Brambilla C., et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996, 149(6):1941-1952.
36. Bolon I., Gouyer V., Devouassoux M., Vandenbunder B., Wernert N., Moro D., et al. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 1995, 147(5):1298-1310.
37. Gazzeri S., Della Valle V., Chaussade L., Brambilla C., Larsen C.J., Brambilla E. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998, 58(17):3926-3931.
38. Brambilla E., Constantin B., Drabkin H., Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 2000, 156(3):939-950.
39. Brambilla E., Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 2009, 33(6):1485-1489.
40. Stewart D.J., Johnson C., Lopez A., Glisson B., Rhee J.M., Bekele B.N. Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. J Thorac Oncol 2010, 5(11):1826-1834.